PHARMACYTE BIOTECH INC (PMCB) Stock Price & Overview
NASDAQ:PMCB • US71715X2036
Current stock price
The current stock price of PMCB is 0.7801 USD. Today PMCB is up by 1.31%. In the past month the price increased by 0.01%. In the past year, price decreased by -36.06%.
PMCB Key Statistics
- Market Cap
- 8.378M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.05
- Dividend Yield
- N/A
PMCB Stock Performance
PMCB Stock Chart
PMCB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PMCB. When comparing the yearly performance of all stocks, PMCB is a bad performer in the overall market: 89.02% of all stocks are doing better.
PMCB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PMCB. No worries on liquidiy or solvency for PMCB as it has an excellent financial health rating, but there are worries on the profitability.
PMCB Earnings
PMCB Forecast & Estimates
PMCB Groups
Sector & Classification
PMCB Financial Highlights
Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -195.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.4% | ||
| ROE | -19% | ||
| Debt/Equity | 0 |
PMCB Ownership
PMCB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PMCB
Company Profile
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Company Info
IPO: 2003-09-11
PHARMACYTE BIOTECH INC
3960 Howard Hughes Parkway, Suite 500
Las Vegas NEVADA US
CEO: Kenneth L. Waggoner
Employees: 2
Phone: 19175952850
PHARMACYTE BIOTECH INC / PMCB FAQ
What does PMCB do?
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Can you provide the latest stock price for PHARMACYTE BIOTECH INC?
The current stock price of PMCB is 0.7801 USD. The price increased by 1.31% in the last trading session.
What is the dividend status of PHARMACYTE BIOTECH INC?
PMCB does not pay a dividend.
What is the ChartMill technical and fundamental rating of PMCB stock?
PMCB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is PHARMACYTE BIOTECH INC (PMCB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PMCB.
Can you provide the ownership details for PMCB stock?
You can find the ownership structure of PHARMACYTE BIOTECH INC (PMCB) on the Ownership tab.
What is the Short Interest ratio of PHARMACYTE BIOTECH INC (PMCB) stock?
The outstanding short interest for PHARMACYTE BIOTECH INC (PMCB) is 0.96% of its float.